ArticleArchives of gynecology and obstetrics2026
Severe maternal morbidity in patients of advanced maternal age with and without metabolic syndrome.
Article in Archives of gynecology and obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo estimate the burden of metabolic syndrome (MetS) on severe maternal morbidity (SMM) in women of advanced maternal age (AMA), quantify age-related escalation in SMM risk, and evaluate sociodemographic influences.
methodsWe retrospectively conducted a cross-sectional, population-level analysis of the Nationwide Inpatient Sample (Q4 2015-2019), a discharge-level database, to identify delivery hospitalizations among patients aged ≥ 35 years. MetS was defined by ICD-10 codes indicating ≥ 3 of the following: hypertension, type 2 diabetes, obesity, hypertriglyceridemia, or low high-density lipoprotein cholesterol. The primary outcome was SMM as defined by the Centers for Disease Control and Prevention; a secondary outcome excluded blood transfusion. Multivariable logistic regression adjusted for race, income quartile, primary payer, hospital characteristics, and substance use. Weighted adjusted odds ratios (AORs) with 95% confidence intervals (CIs) were reported.
resultsAmong 3.1 million delivery hospitalizations, 556,609 (17.8%) occurred in AMA patients; 12,188 (2.2%) experienced SMM and 6,528 (1.2%) experienced nontransfusion SMM. SMM was significantly higher among patients with MetS compared to those without (7.37% vs 2.17%; nontransfusion SMM: 5.36% vs 1.16%). SMM rates increased with advancing age. After adjustment, MetS was associated with markedly increased odds of SMM (AOR 2.75, 95% CI 2.29-3.30) and nontransfusion SMM (AOR 3.59, 95% CI 2.90-4.44), both p < 0.001.
conclusionMetS is associated with SMM risk among AMA patients, independent of sociodemographic factors, with risk increasing further at older maternal ages. This study quantifies the disproportionate burden of MetS in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.